Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Patrick Anquetil sat down with ASAP Biopharma ahead of his keynote "Alliance Managers Are Bringing Digital Health Innovation" which is slated for 10:20 a.m. EDT on September 28th. The keynote will be followed by a Q&A session.
Patrick Anquetil, PhD, MBA sat down with ASAP Biopharma ahead of his keynote “Alliance Managers Are Bringing Digital Health Innovation” which is slated for 10:20 a.m. EDT on September 28th. Dr. Anquetil will reveal how Portal’s alliance governance, framework, and execution are inextricably linked to the advancement of this groundbreaking drug-delivery mechanism. After the keynote Dr. Anquetil plans to have a Q&A session and discussion of any aspect of innovation that isn’t covered in his presentation, including but not limited to issues related to regulatory, manufacturing, and commercial phases of the drug development life cycle.
Read the full interview here: ASAP BioPharma Conference Keynote Preview: Alliance Managers Are Bringing Digital Health Innovation
Despite recent innovations, like the launch in Europe of the first electromechanical reusable and connected auto-injector (UCB’s CIMZIA ava Connect® in early 2021), almost all new biologic drugs are launched with specific and undifferentiated self-injection options...
The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Needles are a 150-year-old technology. The world around us is rapidly evolving but drug delivery has not made the same technological strides that other medical devices have. Portal Instruments is looking to change that with a highly innovative needle-free drug delivery injector.
Please fill out the details below and we will get back to you shortly.